February 07, 2024 BY Elizabeth Anderson
Novartis broadening horizons with bolt-on MorphoSys acquisition
This per-share takeover price is significantly higher than the German manufacturer’s going market performance. At the final bell on Monday, MorphoSys’s Nasdaq shares priced at $17.27. Bloomberg claimed that this acquisition was an attempt by Vasant Narasimhan, the Novartis CEO, to prove to investors that he could drive financial and organisational growth. After disappointing financial…
Read more